Healio

Inhaled amikacin lowers incidence of ventilator-associated pneumonia

Please provide your email address to receive an email when new articles are posted on . Ventilator-associated pneumonia occurred less frequently in patients who received inhaled amikacin vs. placebo.
Monthly Prescribing Reference

Survey: Management of Amikacin Liposome Inhalation Suspension-Associated Respiratory Adverse Events

Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea. Results from a ...
Healio

Inhalation therapy containing manuka honey, amikacin shows promise for respiratory infections

Please provide your email address to receive an email when new articles are posted on . Combining manuka honey and the antibiotic amikacin in a lab-based nebulization formulation was effective for ...
Nasdaq

Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal ...

BRIDGEWATER, N.J., March 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Pharmabiz

Insmed announces positive results from phase 3 CONVERT study of Arikayce in patients with refractory MAC lung disease

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, presented new data from the ongoing phase 3 CONVERT study of ...
Business Wire

Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq GS:INSM) today reported results from the Company’s phase 2 clinical trial of ARIKAYCE TM, or liposomal amikacin for inhalation, ...
Business Insider

Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

ARIKAYCE ® (amikacin liposome inhalation suspension) is delivered by a novel inhalation device, the Lamira Nebulizer System, developed by PARI. Lamira is a quiet, portable nebulizer that enables ...
Finanznachrichten

PARI Pharma's eFlow Technology device, LAMIRA, approved as the only nebulizer system to deliver Insmed's ARIKAYCE (amikacin liposome inhalation suspension)

- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
PharmaTimes

Bayer/Nektar experimental inhaled antibiotic fails in Phase III

Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia. Bayer and Nektar Therapeutics’ ...
Business Insider

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...
FierceBiotech

Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication

RICHMOND, Va., March 21, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct ...